Daiichi Sankyo Limited

6 days ago · businesswire.com

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026. “Strong revenue growth continues in the second quarter of fiscal year 2026, driven by Enhertu and Datroway. These medicines have received nine new approvals across multiple indications since last quarter, including same day breast cancer approvals in Japan and China, which will allow us to bring these medicines to more patients,” said Hiroyuki Okuz.

8 days ago · businesswire.com

MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinuation remains a pe.

15 days ago · businesswire.com

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO.

1 month ago · reuters.com

AstraZeneca and Daiichi Sankyo have entered into ​a clinical collaboration with ‌Summit Therapeutics to test their cancer drug, Datroway, in ​combination with Summit's ​ivonescimab across multiple tumour types, ⁠including lung and breast ​cancers.

1 month ago · reuters.com

Merck ​and Daiichi ‌Sankyo have ​voluntarily ​withdrawn their ⁠US ​application ​seeking accelerated approval ​for ​their experimental lung ‌cancer ⁠therapy, the ​drugmakers ​said ⁠on Friday.

2 months ago · businesswire.com

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.

3 months ago · businesswire.com

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and Datroway were received in a single week in May, underscoring the continued strength of our portfolio where.